share_log

百奥泰(688177.SH):Avzivi获欧盟委员会上市批准

Bio-thera Solutions (688177.SH): Avzivi receives European Commission approval for listing.

Gelonghui Finance ·  Jul 30 03:58

Bio-Thera Solutions (688177.SH) announced on July 30th that it has recently received notification from the European Union Commission that Avzivi (BAT1706, Bevacizumab Injection) has been approved for marketing by the European Union Commission for the treatment of metastatic colorectal cancer, metastatic breast cancer, non-small cell lung cancer, renal cell carcinoma, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, cervical cancer.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment